Patents by Inventor Markus Buergle

Markus Buergle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
    Patent number: 7807681
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: October 5, 2010
    Assignee: Wilex AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS
    Publication number: 20100068272
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Application
    Filed: September 14, 2009
    Publication date: March 18, 2010
    Applicant: WILEX AG
    Inventors: Stefan SPERL, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
    Patent number: 7608623
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: October 27, 2009
    Assignee: Wilex AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
    Publication number: 20080261998
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 23, 2008
    Applicant: WILEX AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Cyclic peptidomimetic urokinase receptor antagonists
    Patent number: 7314863
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Grant
    Filed: December 30, 2005
    Date of Patent: January 1, 2008
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Buergle, Nils Potthoff, Niko Schmiedeberg
  • Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
    Publication number: 20060142305
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Application
    Filed: November 28, 2005
    Publication date: June 29, 2006
    Applicant: WILEX AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Cyclic peptidomimetic urokinase receptor antagonists
    Publication number: 20060105943
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Application
    Filed: December 30, 2005
    Publication date: May 18, 2006
    Applicant: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Buergle, Nils Potthoff, Niko Schmiedeberg
  • Cyclic peptidomimetic urokinase receptor antagonists
    Patent number: 7045504
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 16, 2006
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Buergle, Nils Potthoff, Niko Schmiedeberg